Sickle Cell Disease Cell and Gene Therapy (CGT) Access Policy
Customize your policy alerts
Sign up for all Ohio Department of Medicaid policy alerts
Know when Ohio Department of Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Ohio Medicaid coverage and prior authorization for Casgevy and Lyfgenia in beneficiaries with sickle cell disease through the CMS Cell and Gene Therapy Access Model, provided through the Medicaid medical benefit except for dually eligible beneficiaries enrolled in MyCare Ohio.
No material clinical or coverage changes in this revision.
Coverage Criteria
All-products criteria
Covered when ALL of the following all-products criteria are met:
All Products
Eligibility and enrollment
- The beneficiary is currently enrolled in Ohio Medicaid Fee-for-Service or Managed Medicaid; has sickle cell disease confirmed by genetic testing; and is at least 12 years of age at the expected time of gene therapy administration.Age ≥12 years
Clinical and provider requirements
- The beneficiary is clinically stable and fit for transplantation, and the medication is prescribed by or in consultation with a board-certified hematologist with sickle cell disease expertise.
Treatment center and registry requirements
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.